Jasper Therapeutics, Inc. - JSPR Net earnings per share for the last 12 months

This chart illustrates the EPS (TTM) dynamics for Jasper Therapeutics (JSPR), which currently stands at 73.90. The company's US laboratories are developing methods to optimize patient preparation for cell transplantation. A strong scientific foundation is supported by massive investments in the development of unique antibodies. The business is currently implementing industrial manufacturing standards for its drugs, which temporarily increases the share of research expenses due to a lack of revenue.
Financial and market metric breakdowns for Jasper Therapeutics, Inc. (JSPR)

This indicator calculates the percentage change in net earnings per share over the last twelve months relative to the same period last year, measuring real income growth rates. By analyzing the annual EPS (ttm) growth rate, an investor assesses the cost efficiency of Jasper Therapeutics (JSPR) regarding R&D and option programs within the context of the business's capitalization.